2.02

0.00% 0.00

After Hours: 2.02

Black Diamond Therapeutics Inc (BDTX)

Overview News Price History Option Chain Financials Discussions Forecast

Black Diamond Therapeutics Inc stock is traded at $2.02, with a volume of 330.30K. It is up +0.00% in the last 24 hours and up +8.60% over the past month. Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Previous Close:

$2.02

Open:

$2.01

24h Volume:

330.30K

Relative Volume:

0.21

Market Cap:

$116.06M

Revenue:

$70.00M

Net Income/Loss:

$-43.21M

P/E Ratio:

-2.6653

EPS:

-0.7579

Net Cash Flow:

$-34.03M

1W Performance:

+3.59%

1M Performance:

+8.60%

6M Performance:

-9.01%

1Y Performance:

-27.60%

1-Day Range:

$1.9601

$2.045

1-Week Range:

$1.9302

$2.14

52-Week Range:

$1.60

$4.94

Black Diamond Therapeutics Inc Stock (BDTX) Company Profile

Name

Black Diamond Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

617-417-5868

Address

245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

BDTX's Discussions on Twitter

Compare BDTX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BDTX Black Diamond Therapeutics Inc	2.02	120.65M	70.00M	-43.21M	-34.03M	-0.7579
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-25	Downgrade	Guggenheim	Buy → Neutral
Nov-18-25	Resumed	Piper Sandler	Overweight
Oct-16-25	Resumed	Stifel	Buy
Sep-04-25	Initiated	Guggenheim	Buy
Jul-01-25	Resumed	Raymond James	Outperform
Jul-31-24	Initiated	Raymond James	Outperform
Jul-14-23	Initiated	Piper Sandler	Overweight
Jun-30-23	Upgrade	Stifel	Hold → Buy
Jun-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-27-23	Upgrade	Wedbush	Neutral → Outperform
Mar-29-22	Downgrade	Wedbush	Outperform → Neutral
Mar-22-22	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-30-21	Initiated	Stifel	Hold
Jan-07-21	Initiated	Wedbush	Outperform
Nov-24-20	Initiated	Berenberg	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	Canaccord Genuity	Buy
Feb-24-20	Initiated	Cowen	Outperform
Feb-24-20	Initiated	JP Morgan	Overweight
Feb-24-20	Initiated	Jefferies	Buy

View All

Black Diamond Therapeutics Inc Stock (BDTX) Latest News

Aug 11, 2026

Black Diamond Settles HMI Cancer-Drug Discovery Patent Lawsuit - news.bloomberglaw.com

Aug 11, 2026

Aug 10, 2026

Weekly Recap: Silevertinib NSCLC Phase 2 efficacy and $110.5M cash runway - TradingView

Aug 10, 2026

Aug 08, 2026

Renaissance Technologies LLC Has $3.50 Million Stock Holdings in Black Diamond Therapeutics, Inc. $BDTX - MarketBeat

Aug 08, 2026

Aug 07, 2026